Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin Publisher Pubmed



Goodarzi N¹ ; Barazesh Morgani A² ; Abrahamsson B³ ; Cristofoletti R⁴ ; Groot DW⁵ ; Langguth P⁶ ; Mehta MU⁷ ; Polli JE⁸ ; Shah VP⁹ ; Dressman JB¹⁰
Source: Journal of Pharmaceutical Sciences Published:2016

Abstract

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release solid oral dosage forms containing ribavirin are reviewed. Ribavirin is highly soluble, but its permeability characteristics are not well defined. Therefore according to the Biopharmaceutical Classification System, and taking a worst case approach, ribavirin should be assigned to class III. As ribavirin is transported across the brush border membrane of the human jejunum by hCNT2, it shows saturable uptake in the intestine. However, no common excipients have been shown to compete for ribavirin absorption, nor have problems with BE of immediate release ribavirin formulations containing different excipients and produced by different manufacturing methods been reported in the open literature. So the risk of bioinequivalence caused by these factors appears to be low. Ribavirin is considered a narrow therapeutic index drug, as judged by comparing the minimum effective concentration and minimum toxic concentrations in blood. Although ribavirin would not be eligible for approval via a Biopharmaceutical Classification System-based biowaiver procedure according to today's guidances due to its narrow therapeutic index, the risks of biowaiving should be weighed against the considerable risks associated with studying BE of ribavirin products in healthy subjects. © 2016 American Pharmacists Association®.